SUMMARY
PK
Horizant®, the only gabapentin prodrug, offers extended absorption1,2,6- Horizant® delivers 2x greater bioavailability vs conventional gabapentin2
RLS
- Horizant® is the only alpha-2-delta ligand indicated for moderate-to-severe primary RLS in adults1,3,4
- With Horizant®, most patients experienced RLS symptom relief as early as week 18
- Horizant® is well tolerated in adults with moderate-to-severe primary RLS1
RLS GUIDELINES
- Gabapentin enacarbil (Horizant®) is the ONLY FDA-approved treatment for RLS that is strongly recommended by the AASM Clinical Practice Guidelines5,a
PHN
- Horizant® is the only gabapentin prodrug6
- Patients on placebo discontinued treatment at higher rates than patients on Horizant®1
DOSING
- With Horizant®, finding the right dose is possible1,b
- Once-daily dosing, no titration required for RLS1
- Single-step titration, twice-daily dosing for PHN1
aStrong recommendation moderate certainty of evidence; based on 8 randomized controlled trials and 3 observational studies.5
bPlease see dosing for specific patient populations. For patients with renal impairment, geriatric use, and use with CNS depressants, please see dosing in the full Prescribing Information.
Horizant® is not interchangeable with other gabapentin products.1
The clinical significance of the PK data for Horizant® and gabapentin is unknown.
